[go: up one dir, main page]

AR026022A1 - Metodo para el tratamiento de la obesidad - Google Patents

Metodo para el tratamiento de la obesidad

Info

Publication number
AR026022A1
AR026022A1 ARP000105369A ARP000105369A AR026022A1 AR 026022 A1 AR026022 A1 AR 026022A1 AR P000105369 A ARP000105369 A AR P000105369A AR P000105369 A ARP000105369 A AR P000105369A AR 026022 A1 AR026022 A1 AR 026022A1
Authority
AR
Argentina
Prior art keywords
obesity
treatment
solvatofarma
animal
pharmaceutically acceptable
Prior art date
Application number
ARP000105369A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924275.2A external-priority patent/GB9924275D0/en
Priority claimed from GB0001861A external-priority patent/GB0001861D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR026022A1 publication Critical patent/AR026022A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Método para el tratamiento de la obesidad que comprende administrar a un animal que necesite del mismo, un compuesto de formula (1) o una sal o solvatofarmacéuticamente aceptable del mismo. Los métodos para la supresion del apetito, para causarpérdi da de peso, para prevenir el aumento de peso, para afectarpreferencialmente la composicion grasa del cuerpo, para inhibir el antojo del alimento, o para mantener el peso bajo también se describen.
ARP000105369A 1999-10-13 2000-10-12 Metodo para el tratamiento de la obesidad AR026022A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924275.2A GB9924275D0 (en) 1999-10-13 1999-10-13 Method for the treatment of obesity
GB0001861A GB0001861D0 (en) 2000-01-28 2000-01-28 Method for the treatment of obesity

Publications (1)

Publication Number Publication Date
AR026022A1 true AR026022A1 (es) 2002-12-26

Family

ID=26243494

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000105369A AR026022A1 (es) 1999-10-13 2000-10-12 Metodo para el tratamiento de la obesidad

Country Status (6)

Country Link
EP (1) EP1220673A2 (es)
JP (1) JP2003511410A (es)
AR (1) AR026022A1 (es)
AU (1) AU7750100A (es)
PE (1) PE20010744A1 (es)
WO (1) WO2001026641A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1414518A4 (en) 2001-08-08 2009-01-21 Kevin R Orton APPARATUS AND METHOD FOR ELECTRICAL CONDUCTION SLIMMING
WO2003097046A1 (en) 2002-05-17 2003-11-27 Duke University Method for treating obesity
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
JP2011506298A (ja) * 2007-12-05 2011-03-03 アストラゼネカ アクチボラグ 新規化合物iv
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
CA2726646A1 (en) * 2008-06-04 2009-12-10 Astrazeneca Ab New compounds vii
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
RS60682B1 (sr) 2012-06-06 2020-09-30 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
AU744261B2 (en) * 1997-04-24 2002-02-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating eating disorders
WO1999025355A1 (en) * 1997-11-14 1999-05-27 Glaxo Group Ltd. Method of treating addiction to nicotine products
NZ529316A (en) * 1998-01-21 2004-05-28 Glaxo Group Ltd Pharmaceutically active morpholinol
MA26693A1 (fr) * 1998-09-28 2004-12-20 Glaxo Group Ltd Compositions pour administration par voie buccale

Also Published As

Publication number Publication date
AU7750100A (en) 2001-04-23
JP2003511410A (ja) 2003-03-25
WO2001026641A2 (en) 2001-04-19
EP1220673A2 (en) 2002-07-10
WO2001026641A3 (en) 2002-01-10
PE20010744A1 (es) 2001-07-23

Similar Documents

Publication Publication Date Title
MX2024007720A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
KR950010890A (ko) 폐경기 증후군의 치료방법
CY1105000T1 (el) Χρηση της σπινοσαδης ή μιας συνθεσεως περιεχουσης σπινοσαδη
CO6331425A2 (es) Composiciones que comprenden n-(3,4-difluoro-2-(2-fluoro-4-yodofenilamino)6-metoxifenil)-1-(2,3-dihidroxiproxipropil)ciclopropan-1-sulfamida
AR030933A1 (es) Derivados del triazol y composiciones farmaceuticas que los contienen
DOP2004001052A (es) Inhibidores heterociclil amino de 11-beta-hidroxiesteroide deshidrogenasa tipo 1
KR930003912A (ko) 울혈성 심장 마비 치료법
CL2023000196A1 (es) Compuestos de tetrahidropirazolo-pirazinil-dihidroimidazolona o tetrahidropirazolo-piridinil-dihidroimidazolona y métodos de uso de los mismos
CO5251429A1 (es) Derivados de ter-butil-(7-metil-imidazo(1,2-a)piridin-3- il)-amina procedimiento para su preparacion, medicamentos que los contienen, su uso para la preparacion de un medicamento para la inhibicion de la no-sintasa y composiciones farmaceuticas que l
KR930019637A (ko) 비페닐설포닐우레아 또는 비페닐설포닐우레탄 측쇄를 갖는 이미다졸 유도체, 이의 제조방법 및 용도
PA8591701A1 (es) Derivados de pirrolopirimidina
CY1109242T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου
AR026022A1 (es) Metodo para el tratamiento de la obesidad
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
CR7510A (es) DERIVADOS DE [1-4] DIAZEPINO[6,7,1-iJ)] QUINOLONA COMO AGENTES ANTIPSICOTICOS Y CONTRA LA OBESIDAD
CY1106763T1 (el) Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου
PL356252A1 (en) Synergistic combination of pde inhibitors and beta 2 adrenoceptor agonist
TR200102646T2 (tr) Yeme bozukluklarının tedavi edilmesi.
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
AR039190A1 (es) Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto
TR200101633T2 (tr) Farmasötik bileşim
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
AR014964A1 (es) Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones
RU2019121690A (ru) Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer